The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
POLITICAL PRISONERS VS DEPORTEES: Venezuela’s prosecutor’s office slammed the call by El Salvador’s leader, accusing him of crimes against humanity Salvadoran President Nayib Bukele on Sunday proposed carrying out a prisoner swap with Venezuela, suggesting he would exchange Venezuelan deportees from the US his government has kept imprisoned for what he called “political prisoners” in Venezuela. In a post on X, directed at Venezuelan President Nicolas Maduro, Bukele listed off a number of family members of high-level opposition figures in Venezuela, journalists and activists detained during the South American government’s electoral crackdown last year. “The only reason they are imprisoned is for having opposed you and your electoral fraud,” he wrote to Maduro. “However, I want to propose a humanitarian agreement that
ECONOMIC WORRIES: The ruling PAP faces voters amid concerns that the city-state faces the possibility of a recession and job losses amid Washington’s tariffs Singapore yesterday finalized contestants for its general election on Saturday next week, with the ruling People’s Action Party (PAP) fielding 32 new candidates in the biggest refresh of the party that has ruled the city-state since independence in 1965. The move follows a pledge by Singaporean Prime Minister Lawrence Wong (黃循財), who took office last year and assumed the PAP leadership, to “bring in new blood, new ideas and new energy” to steer the country of 6 million people. His latest shake-up beats that of predecessors Lee Hsien Loong (李顯龍) and Goh Chok Tong (吳作棟), who replaced 24 and 11 politicians respectively
Young women standing idly around a park in Tokyo’s west suggest that a giant statue of Godzilla is not the only attraction for a record number of foreign tourists. Their faces lit by the cold glow of their phones, the women lining Okubo Park are evidence that sex tourism has developed as a dark flipside to the bustling Kabukicho nightlife district. Increasing numbers of foreign men are flocking to the area after seeing videos on social media. One of the women said that the area near Kabukicho, where Godzilla rumbles and belches smoke atop a cinema, has become a “real
‘WATER WARFARE’: A Pakistani official called India’s suspension of a 65-year-old treaty on the sharing of waters from the Indus River ‘a cowardly, illegal move’ Pakistan yesterday canceled visas for Indian nationals, closed its airspace for all Indian-owned or operated airlines, and suspended all trade with India, including to and from any third country. The retaliatory measures follow India’s decision to suspend visas for Pakistani nationals in the aftermath of a deadly attack by shooters in Kashmir that killed 26 people, mostly tourists. The rare attack on civilians shocked and outraged India and prompted calls for action against their country’s archenemy, Pakistan. New Delhi did not publicly produce evidence connecting the attack to its neighbor, but said it had “cross-border” links to Pakistan. Pakistan denied any connection to
RSS